Trade Ligand Pharmaceuticals Incorpor - LGND CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.27 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 70.07 |
| Open | 69.95 |
| 1-Year Change | -8.12% |
| Day's Range | 69.95 - 71.7 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2024 | 70.07 | 0.58 | 0.83% | 69.49 | 70.88 | 68.91 |
| Apr 24, 2024 | 70.65 | 1.96 | 2.85% | 68.69 | 70.84 | 68.44 |
| Apr 23, 2024 | 69.82 | 1.94 | 2.86% | 67.88 | 71.04 | 67.58 |
| Apr 22, 2024 | 68.22 | -3.49 | -4.87% | 71.71 | 72.46 | 67.53 |
| Apr 19, 2024 | 72.14 | 1.03 | 1.45% | 71.11 | 72.81 | 70.85 |
| Apr 18, 2024 | 72.45 | -5.19 | -6.68% | 77.64 | 77.94 | 72.26 |
| Apr 17, 2024 | 78.43 | -0.27 | -0.34% | 78.70 | 80.15 | 77.71 |
| Apr 16, 2024 | 79.25 | 1.21 | 1.55% | 78.04 | 81.20 | 78.04 |
| Apr 15, 2024 | 79.53 | 0.44 | 0.56% | 79.09 | 80.66 | 78.52 |
| Apr 12, 2024 | 81.23 | 0.83 | 1.03% | 80.40 | 81.41 | 79.64 |
| Apr 11, 2024 | 81.32 | 1.04 | 1.30% | 80.28 | 81.33 | 79.96 |
| Apr 10, 2024 | 80.64 | 1.45 | 1.83% | 79.19 | 80.85 | 78.27 |
| Apr 9, 2024 | 81.43 | 4.21 | 5.45% | 77.22 | 81.46 | 77.22 |
| Apr 8, 2024 | 76.51 | -1.01 | -1.30% | 77.52 | 79.95 | 76.51 |
| Apr 5, 2024 | 77.78 | 1.47 | 1.93% | 76.31 | 78.06 | 75.43 |
| Apr 4, 2024 | 77.82 | -0.09 | -0.12% | 77.91 | 78.50 | 76.32 |
| Apr 3, 2024 | 74.54 | 3.18 | 4.46% | 71.36 | 74.76 | 70.96 |
| Apr 2, 2024 | 72.69 | 0.62 | 0.86% | 72.07 | 73.17 | 71.65 |
| Apr 1, 2024 | 73.45 | 1.79 | 2.50% | 71.66 | 73.49 | 70.85 |
| Mar 28, 2024 | 72.46 | 1.63 | 2.30% | 70.83 | 72.98 | 70.55 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ligand Pharmaceuticals Incorpor Company profile
About Ligand Pharmaceuticals Inc.
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company. The Company is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. It has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development or research and are fully funded by its collaboration partners and licensees. Its technologies include OmniAb Technologies, Pelican Expression Technology Platform, Captisol Technology, HepDirect, LTP, BEPro Technology Platform, and SUREtechnology Platform. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies. The Pelican Expression Technology is a scalable platform for recombinant protein production and is suited for complex, large-scale protein production. Captisol is a chemically modified cyclodextrin designed to optimize the stability of drugs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Ligand Pharmaceuticals Inc. revenues increased 49% to $277.1M. Net income totaled $57.1M vs. loss of $3M. Revenues reflect Captisol segment increase of 49% to $164.3M, Milestone segment increase from $11.5M to $28.7M. Net Income reflects Gain (loss) from short-term investments decrease of 76% to $4M (expense), Other General and administrative decrease of 23% to $36.1M (expense).
Equity composition
Common Stock $.006 Par, 3/11, 33,333,3333 auth., 20,644,234 issd., less 1,118,222 shs in Treas. @ $42.3M. Insiders own 3.36%. IPO:11/92, 4.3M Class A shares @ $11 by Lehman Bros. FY'00 Q's are restated for SAB 101 adjustment. 9/05,Co. delisted from NASDAQ to OTC.11/10, 1-for-06 Reverse Stock split.
| Industry: | Pharmaceuticals (NEC) |
3911 Sorrento Valley Blvd
Suite 110
SAN DIEGO
CALIFORNIA 92121
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com